Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

摘要: Purpose Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR-expressing non‐small-cell lung cancer previously treated platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement. Patients Methods Fifty-seven received an oral, continuous daily dose 150 mg erlotinib. Assessments objective response used WHO Response Evaluation Criteria Solid Tumors criteria. The European Organization for Research Treatment Cancer Quality Life Questionnaire C30, supplemented module, LC13, was to measure health-related quality life. Additional analyses were performed identify predictors survival. Results rate 12.3% (95% CI, 5.1% 23.7%). Responses observed regardless type or number prior regimens. Median survival time 8.4 months 4.8 13.9 months), the 1-year 40% 28% 54%). therapy associated tumor-related drug well tolerated; drug-related cutaneous rash diarrhea 75% 56% patients, respectively. One patient experienced toxicity consisting severe grade 3 diarrhea. Time since diagnosis good performance status significant multivariate Cox proportional hazards model, whereas HER1/EGFR staining intensity not. Additionally, correlated occurrence severity rash.